This article is more than 5 years old. Information may no longer be current.

TargeGen initiates phase 1 safety study of topical drug for AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — TargeGen Inc. has initiated a phase 1 trial evaluating TG100801, a topical multi-targeted kinase inhibitor, for treating macular degeneration and other ocular conditions, the company announced.

The trial will involve roughly 45 patients and is expected to be completed by the end of the first quarter of 2007. TargeGen plans to initiate phase 2 studies in mid-2007, according to a press release.

TG100801, applied daily in eye-drop form, is designed to suppress disease-related edema, angiogenesis and inflammation. The company believes the drug may offer equal or superior efficacy to injectable agents such as VEGF inhibitors, company officials said in the release.